|
Pharmacoepidemiology & Pharmacogenomics Resources:
Mention of companies, products or services on this Web site is for reference purposes only
and does not constitute endorsement by NCI or the US Government.
Please read our disclaimer.
|
|
Serious Adverse Events Consortium (SAEC)
Description
The international Serious Adverse Events Consortium (SAEC) is a global, non-profit
partnership between leading pharmaceutical companies, the FDA, and academic institutions
which plans to identify and validate genetic markers that may help predict which
individuals are at risk for serious adverse drug events. The goal of the consortium is to
publish a set of predictive SNPs for all drug-related serious adverse events (SAEs),
reducing significant patient and economic costs as well as improving the flow of safe and
effective medical advances by addressing safety issues of new drugs before they reach the
market.
|
|